



UNITED STATES PATENT AND TRADEMARK OFFICE

CH
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/509,292

09/23/2004

Dimitrios T. Drivas

MP-01

3709

50446

7590

12/15/2006

HOXIE & TSO LLP
374 MILLBURN AVENUE
SUITE 300 E
MILLBURN, NJ 07041

EXAMINER

CROWDER, CHUN

ART UNIT

PAPER NUMBER

1644

DATE MAILED: 12/15/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**U.S. Patent and Trademark Office**

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

10/509,292

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

CHUN CROWDER

ART UNIT	PAPER
----------	-------

1644 20061202

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on 10/12/2006 is not fully responsive to the prior Office Action because of the following omissions or matters:

As part of this response to the restriction requirement mailed 09/07/2006, applicant has elected with traverse of Group I, drawn to a method for treating a subject, and species of SEQ ID NO:16 conjugated to DT. The traversal was on the ground that Jose et al. (JBC 1994. 179:881-887 Reference cited on IDS filed 01/03/05) do not teach human eotaxin and vaccines or immunogenic conjugates or methods of treatment involving generating an active immune response to eotaxin. This is not found persuasive for reasons of record. Further, it is noted that the instant claims are drawn to eotaxin in general and not to human eotaxin. Furthermore, Jose et al. teach that based on their study human eotaxin can be important in human asthmatic lung (see Results and Discussion on pages 883-886). Since Applicant's inventions do not contribute a special technical feature when viewed over the prior art they do not have a single general inventive concept and so lack unity of invention. Therefore, the Restriction Requirement is deemed proper and is made FINAL. Moreover, applicant has not indicated species of a specific condition as set forth in the Restriction Requirement mailed 09/07/2006 (see Section 9 on pages 4-5).

The restriction requirement indicated that is Group I is elected, applicant is further required to elect a method for treating specific condition (e.g. asthma as recited in claim 2).

As previously stated, applicant has not indicated the elected species of one specific condition.

Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chun Crowder whose telephone number is 571-272-8142. The examiner can normally be reached on 8:30-5:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Phillip Gambel
PHILLIP GAMBEL, PH.D JD
PRIMARY EXAMINER

TL 1600

12/6/06

10/509, 292

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Chun Crowder, Ph.D.

Patent Examiner

December 2, 2006